Lymphomas/CLL

John M. Burke MD and Christopher R. Flowers MD review and share their expert perspectives on key findings in lymphoma/CLL presented at the 2017 ASH annual meeting.

Share

Program Content

Activities

  • R/R HCL: Vemurafenib + Rituximab
    HCL-PG03: Phase II Trial of Vemurafenib + Rituximab in Patients With Relapsed/Refractory Hairy Cell Leukemia
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 11, 2017

  • Acalabrutinib in R/R MCL
    ACE-LY-004: Phase II Trial of BTK Inhibitor Acalabrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 11, 2017

  • CLL: Venetoclax + Ibrutinib
    Phase II Trial of Venetoclax + Ibrutinib in Patients With Relapsed/Refractory or Untreated High-Risk CLL
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 12, 2017

  • Ibrutinib in R/R MCL
    Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma: 3.5-Year Follow-up of a Pooled Analysis of 3 Clinical Trials
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 13, 2017

  • First-line Len + Ritux in MCL
    Extended Follow-up of Mantle Cell Lymphoma Patients Treated With First-line Lenalidomide + Rituximab
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 14, 2017

  • Brentuximab Vedotin + AVD in cHL
    ECHELON-1: Phase III Trial of First-line Brentuximab Vedotin + AVD Chemotherapy in Advanced Classical Hodgkin Lymphoma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 14, 2017

  • Nivolumab After PD in R/R cHL
    Analysis of Nivolumab Continued Beyond Progression in Patients With R/R Classical Hodgkin Lymphoma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 14, 2017

  • MURANO: VEN + R in R/R CLL
    MURANO Interim Analysis: Venetoclax + Rituximab vs Bendamustine + Rituximab in Patients With Relapsed/Refractory CLL
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 15, 2017

  • JULIET: CART in R/R DLBCL
    JULIET: Phase II Primary Analysis of CAR T-Cell Therapy Tisagenlecleucel in Adult Patients With Relapsed/Refractory DLBCL
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 15, 2017

  • R/R DLBCL: Polatuzumab Vedotin
    Randomized Phase II Trial of Polatuzumab Vedotin Addition to Bendamustine + Rituximab in Patients With R/R DLBCL
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 15, 2017

  • R/R cHL: BV + Nivolumab
    Phase I/II Study of Brentuximab Vedotin + Nivolumab for Patients With R/R Classical Hodgkin Lymphoma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 18, 2017

  • R/R CLL: Ibrutinib + Venetoclax
    CLARITY: Feasibility Study of Combination Ibrutinib + Venetoclax in R/R CLL
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 19, 2017

  • MAINTAIN: BR + Ritux Maint in FL
    Phase III MAINTAIN: Extended Rituximab Maintenance in Follicular Lymphoma After First-line Bendamustine + Rituximab
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 20, 2017

  • JCAR017 in R/R NHL
    CAR T-Cell Therapy JCAR017 in R/R DLBCL From TRANSCEND NHL 001: Correlation Between Patient Characteristics and Clinical Outcomes
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 20, 2017

Provided by

ProCE Banner

Supporters

AbbVie

AstraZeneca

Celgene

Genentech TEXT Only

Janssen Biotech Pharmacyclics Abbvie

Jazz Pharmaceuticals, Inc.

Novartis Pharmaceuticals Corporation

Pharmacyclics Inc

Seagen

Takeda Oncology